Ressources
-
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Case study
Search Results
Search across news, resources and pages to quickly find relevant content on our site.
Technical Notes
Enhance drug efficacy with Reaction Phenotyping using efficient Bactosomes. Predict interactions & optimise metabolism variability.
Technical Notes
Discover the importance of aqueous solubility in drug discovery and development. Overcome low solubility obstacles with our kinetic and thermodynamic solubility assays. Improve drug absorption and formulation. Explore our DMPK/ADME capabilities now!
Technical Notes
Uncover CYP induction's impact on drug interactions & metabolism. Stay FDA-compliant with CYP1A2, CYP2B6, & CYP3A4 investigations.
Technical Notes
Discover precise cytotoxicity testing with Sygnature's Cell Viability assay. Efficient, innovative, and informed drug safety assessment.
Technical Notes
Explore In Vivo Pharmacokinetic (PK) Studies: Learn about drug absorption, distribution, metabolism, and elimination (ADME). Discover the key parameters - AUC, Cmax, t½, Vss, and clearance - in early-stage drug development. Uncover insights into oral bioavailability and first-pass hepatic elimination. Enhance your understanding of PK through detailed ADME analysis and renal/biliary clearance studies.
Technical Notes
Explore our ready-to-use Dietary-Induced Obese (DIO) mouse and rat models, perfect for assessing weight loss interventions and testing novel treatments. Our DIO mouse model boasts stable weight, significant adiposity, insulin resistance, lipid deposition, and elevated plasma lipids. Experience proven predictive validity in a 4-week study, showcasing the effectiveness of semaglutide. Additionally, our DIO rat model, replicating a calorie-dense Western diet, offers excellent predictive validity with on-demand production in just 16 weeks.
Technical Notes
Explore our rapid model of glucocorticoid-induced insulin resistance, ideal for testing antidiabetic potential of new drugs. Witness the inhibitory effects of mifepristone and CORT125134 on insulin resistance and hyperglycaemia in rats.
Technical Notes
Explore our genetic models of insulin resistance and type 2 diabetes. Our expertise lies in working with animal models predisposed to these conditions, such as ob/ob mice, db/db mice, and Zucker fatty rats. Discover how liraglutide, a clinically approved treatment, mitigates the progression of diabetes in the db/db mouse model. Our standard readouts include glucose tolerance tests and pancreatic insulin quantification. Uncover insights into therapeutic interventions and better understand diabetes-related phenotypes.
Technical Notes
We have developed a robust and reproducible model of diabetes that combines exposure to a…
Technical Notes
Hypophagic potential: Acute Feeding Studies with novel drugs in mice and rats. Rapid assessment, various routes, up to 7-day evaluation. Discover ED50 values & pharmacokinetics. Advance drug development
Technical Notes
The mechanisms underlying the reduction in body weight produced by novel anti-obesity drugs should always…
Technical Notes
Explore body composition analysis for weight loss assessment in mice, differentiating fat loss from harmful water and protein reduction. Methods include DEXA and gold-standard techniques for valuable insights into interventions and drug effects.
Technical Notes
Discovering specific effects on food intake: Satiation profiling and pica assessment help identify potential anti-obesity agents.
Technical Notes
Measure glucose tolerance routes in rodents, assess insulin sensitivity, and test antidiabetic potential with Sitagliptin in insulin-resistant models.
Technical Notes
Explore the mechanisms of satiety and reduced food intake through gastric emptying rate assessment. Our direct and indirect models offer insights into drug effects. Validate with clinical opioid agonist loperamide.
Technical Notes
Explore the Adriamycin-induced Model of Focal Segmental Glomerulosclerosis (FSGS) and Fibrosis. Discover how this rodent model mimics human proteinuric kidney disease, offering quick induction of renal injury and a customizable study design for prevention or reversal of the phenotype. Witness the demonstrated effectiveness of Enalapril in preventing and partially reversing the adriamycin-induced phenotype. Unravel new insights into FSGS research today.
Technical Notes
Revolutionary GN research: anti-GBM rodent model mimics human GN, showcasing rapid inflammation, severe proteinuria & effective treatments.
Technical Notes
Zucker diabetic fatty (ZDF-Leprfa/Crl) rats exhibit obesity, insulin resistance, impaired glucose tolerance, hypertension, and renal…
Technical Notes
Non-alcoholic liver disease, or NASH, is the manifestation of metabolic disorder in the liver. The…
Technical Notes
Non-alcoholic steatohepatitis (NASH) and liver fibrosis are associated with an increased risk of developing hepatocellular…
Technical Notes
Explore NASH & fibrosis in ob/ob H-FFC mouse model. Validate treatments for liver disease, obesity, insulin resistance, and co-morbidities.
Support
Can't find what you're looking for?
Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.
